propranolol

Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective antagonist of β-adrenergic receptor (βAR).

Propranolol hydrochloride is a widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse

(R)-Propranolol hydrochloride (Dexpropranolol hydrochloride) is the less active enantiomer of the anti-adrenoceptor (β-adrenoceptor) antagonist propranolol. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist with a high affinity for β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively.

4-Hydroxypropranolol D7 hydrochloride is deuterium-labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochloride is an active metabolite of Propranolol, with a potency comparable to Propranolol. It inhibits β1- and β2-adrenergic receptors

4-Hydroxypropranolol hydrochloride is an active metabolite of Propranolol, with a potency comparable to Propranolol. It inhibits β1- and β2-adrenergic receptors (pA2s: 8.24 and 8.26).

Rac-Propranolol-d7 is a 2H-labeled Rac-Propranolol. Propranolol is an effective β-adrenergic receptor (βAR) antagonist that inhibits β1AR and β2AR, used in cardiovascular and metabolic disease research.

(S)-(-)-Propranolol hydrochloride, an adrenergic receptor antagonist, exhibits potential anticancer activity and may enhance the prognosis of burn patients.

(±)-4-hydroxy Propranolol β-D-glucuronide is a metabolite of (±)-4-hydroxy propranolol , which is a metabolite of propranolol. The apparent half-life of (±)-4-hydroxy propranolol β-D-glucuronide is similar to propranolol and 4-hydroxy propranolol. Propranolol is a β-adrenergic antagonist, and the active enantiomer, (S)-(-)-propranolol , has log Kd values of -8.16, -9.08, and -6.93 for β1, β2, and β3, respectively.

rac-7-hydroxy Propranolol (hydrochloride) is a ring-hydroxylated isomer and metabolite of propranolol that is an antagonist at β-adrenergic receptors (0.95 potency relative to propranolol). It also demonstrates potent vasodilator activity (0.20 potency relative to propranolol; pA2 = 7.58).

5-hydroxy Propranolol is a metabolite of propranolol , a β-adrenergic receptor antagonist. Propranolol is primarily metabolized in the liver, with cytochrome P450 isoform 2D6 directing ring hydroxylation and the generation of 5-hydroxy propranolol and related metabolites.

Propranolol glycol, a metabolite of propranolol, exhibits transient anticonvulsant activity.

Propranolol-d7 (ring-d7) is a deuterated form of Propranolol hydrochloride, which is a non-selective β-adrenergic receptor (βAR) antagonist with high affinity for both β1AR and β2AR, having Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits the binding of [3H]-DHA to rat brain membrane preparations with an IC50 of 12 nM. It is applicable in research related to hypertension, pheochromocytoma, myocardial infarction, arrhythmia, angina, and hypertrophic cardiomyopathy.

4-Hydroxy propranolol-d7 HCl is a deuterated compound of 4-Hydroxy propranolol HCl. 4-Hydroxy propranolol HCl has a CAS number of 14133-90-5. 4-Hydroxypropranolol hydrochloride is an active metabolite of Propranolol, with a potency comparable to Propranolol. It inhibits β1- and β2-adrenergic receptors (pA2s: 8.24 and 8.26).

Propranolol hydrochloride (Standard) is the standard substance of Propranolol hydrochloride, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Propranolol hydrochloride is a widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.

4-Hydroxy Propranolol HCL (Standard) is a reference standard for research and analysis in studies involving 4-Hydroxy Propranolol HCL. 4-Hydroxypropranolol hydrochloride is an active metabolite of Propranolol, with a potency comparable to Propranolol. It inhibits β1- and β2-adrenergic receptors (pA2s: 8.24 and 8.26).

Propranolol‑D7 Hydrochloride (Standard) is a reference standard of Propranolol‑D7 Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications.

Norpropranolol hydrochloride is the active metabolite of Propranolol.

(±)-Desisopropylpropranolol (N-Desisopropylpropranolol) is a metabolite of Propranolol. Propranolol acts as a non-selective β-adrenergic receptor (βAR) antagonist with high affinity for both β1AR and β2AR, having Ki values of 1.8 nM and 0.8 nM, respectively. It inhibits the binding of [3H]-DHA to rat brain membrane preparations with an IC50 of 12 nM. Propranolol is used in studies related to hypertension, pheochromocytoma, myocardial infarction, arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.

Phosphatase-IN-1 (compound II-8), a propranolol derivative, acts as an inhibitor of phosphatidate phosphatase (Pah). It binds to MoPah1 with an affinity constant of 19.8 μM, demonstrating growth inhibition of plant pathogens and anti-fungal properties, while exhibiting no toxicity towards rice seedlings and wheat heads [1].

(R)-(+)-Atenolol ((R)-Atenolol) is a cardioselective beta-1 adrenergic blocker, which properties are similar to propranolol, but without a negative inotropic effect.

Butocrolol is an amino alcohol derivative that exhibits β-blocker, antiarrhythmic, and local anesthetic properties. This compound shares sympathetic inhibition and antiarrhythmic effects similar to propranolol but has weaker local anesthetic effects.

Butocrolol is an amino alcohol derivative characterized by its β-adrenergic blocking, antiarrhythmic, and local anesthetic properties. Its efficacy in sympathetic blockade and antiarrhythmic effects is similar to propranolol, although it exhibits lower local anesthetic activity.

Pranolium is a quaternary dimethyl derivative of Propranolol, a well-known powerful betareceptor-blocking agent.

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol. Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.